1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6D0AC76805E75CBFE65257941003E28BA
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/D0AC76805E75CBFE65257941003E28BA!OpenDocument
18
19OpenDocument
203.85.245.126
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Product Launch Market Entry and Oncology

Oncology Market Education: Informing Patients and Payers

ID: 5166


Features:

4 Info Graphics

20 Data Graphics

196 Metrics

17 Narratives

3 Best Practices


Pages/Slides: 41


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Oncology Market Education: Informing Patients and Payers"

STUDY OVERVIEW

Patient and payer support plays an important part in the success of a new oncology product entering the market. To build this support, oncology launch leaders look for ways to raise awareness among patients and payers. For patients, advocacy groups are key way to learn about new products while on the payer side, it's important for companies to set their new products apart from existing products.

Best Practices, LLC designed this study to explore the best practices in educating, informing and preparing patients and payers for a new oncology product. In particular, this study examines effective collaboration tactics with advocacy groups and how to engage payers. In addition, the study reviews how public relations is an effective tool for reaching both stakeholder groups.

KEY TOPICS

  • Utilizing patient education and advocacy group collaborations to inform patients
  • Focusing on cost and outcomes to enhance early payer education success
  • Using Public Relations and new technologies in order to leverage reach to patients, physicians and payers
  • Using new technologies for educating and informing patients

SAMPLE KEY METRICS
  • Time phase to start each activity for educating patients and advocacy groups
  • Top five most important activities in educating oncology patients and advocacy groups
  • Time phase to start each activity for educating payer and government agencies
  • Top five most important activities for educating payer and government agencies
  • Effectiveness rating of following calls to action leading patients to websites
  • Importance of various tactical elements influencing public relations marketing effectiveness
  • Effectiveness rating of PR tool during the launch period
  • Importance of various tactical elements influencing public relations effectiveness
  • Seven most effective new technologies for educating patients
  • Seven most effective new technologies for educating physicians

SAMPLE KEY FINDINGS
  • Using Public Relations and Technology: New technologies and Public Relations are both “leveraged,” cost-efficient tools for education; both permit less control than companies customarily want. The development and pre-launch cycle offer many opportunities to use new technologies (e.g., social media, Internet, You Tube/video communication channels) to educate physicians, patients, payers and government.
  • Winning Payers on Board: Commence work earlier than in past to win payers, who are increasingly important to market entry in Oncology. Focus on cost and health outcomes; understand that payers need and engineer them increasingly into clinical trials.


METHODOLOGY

The benchmark class includes 34 executives and managers at 26 leading pharmaceutical, biotech and medical device companies. In addition, deep-dive executive interviews were conducted with selected participants to provide qualitative insights and emerging trends.


Industries Profiled:
Pharmaceutical; Biotech; Health Care; Service; Medical Device; Technology; Manufacturing; Consumer Products; Diagnostic; Chemical


Companies Profiled:
GlaxoSmithKline; ARIAD; Pfizer; Integrated Communications Corp.; Novartis; Genitope Corporation; NeoVista; Inc.; Amgen; Novo Nordisk; Johnson & Johnson; AstraZeneca; Roche; Lilly; Bayer; Human Genome Sciences; Boehringer Ingelheim; Nobel Biocare; Abbott; Solvay Pharmaceuticals; Genentech; Sanofi-aventis; Smith & Nephew; Amylin; Janssen Cilag Pharmaceutical; Dr Reddy's Laboratories; Spectrum Pharmaceutical

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.